<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">17005949</PMID>
<DateCompleted>
<Year>2006</Year>
<Month>10</Month>
<Day>05</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>12</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1533-4406</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>355</Volume>
<Issue>13</Issue>
<PubDate>
<Year>2006</Year>
<Month>Sep</Month>
<Day>28</Day>
</PubDate>
</JournalIssue>
<Title>The New England journal of medicine</Title>
<ISOAbbreviation>N. Engl. J. Med.</ISOAbbreviation>
</Journal>
<ArticleTitle>International trial of the Edmonton protocol for islet transplantation.</ArticleTitle>
<Pagination>
<MedlinePgn>1318-30</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Islet transplantation offers the potential to improve glycemic control in a subgroup of patients with type 1 diabetes mellitus who are disabled by refractory hypoglycemia. We conducted an international, multicenter trial to explore the feasibility and reproducibility of islet transplantation with the use of a single common protocol (the Edmonton protocol).</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We enrolled 36 subjects with type 1 diabetes mellitus, who underwent islet transplantation at nine international sites. Islets were prepared from pancreases of deceased donors and were transplanted within 2 hours after purification, without culture. The primary end point was defined as insulin independence with adequate glycemic control 1 year after the final transplantation.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 36 subjects, 16 (44%) met the primary end point, 10 (28%) had partial function, and 10 (28%) had complete graft loss 1 year after the final transplantation. A total of 21 subjects (58%) attained insulin independence with good glycemic control at any point throughout the trial. Of these subjects, 16 (76%) required insulin again at 2 years; 5 of the 16 subjects who reached the primary end point (31%) remained insulin-independent at 2 years.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Islet transplantation with the use of the Edmonton protocol can successfully restore long-term endogenous insulin production and glycemic stability in subjects with type 1 diabetes mellitus and unstable control, but insulin independence is usually not sustainable. Persistent islet function even without insulin independence provides both protection from severe hypoglycemia and improved levels of glycated hemoglobin. (ClinicalTrials.gov number, NCT00014911 [ClinicalTrials.gov].).</AbstractText>
<CopyrightInformation>Copyright 2006 Massachusetts Medical Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Shapiro</LastName>
<ForeName>A M James</ForeName>
<Initials>AM</Initials>
<AffiliationInfo>
<Affiliation>Clinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada. shapiro@islet.ca</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ricordi</LastName>
<ForeName>Camillo</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hering</LastName>
<ForeName>Bernhard J</ForeName>
<Initials>BJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Auchincloss</LastName>
<ForeName>Hugh</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lindblad</LastName>
<ForeName>Robert</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Robertson</LastName>
<ForeName>R Paul</ForeName>
<Initials>RP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Secchi</LastName>
<ForeName>Antonio</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Brendel</LastName>
<ForeName>Mathias D</ForeName>
<Initials>MD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Berney</LastName>
<ForeName>Thierry</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Brennan</LastName>
<ForeName>Daniel C</ForeName>
<Initials>DC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cagliero</LastName>
<ForeName>Enrico</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Alejandro</LastName>
<ForeName>Rodolfo</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ryan</LastName>
<ForeName>Edmond A</ForeName>
<Initials>EA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>DiMercurio</LastName>
<ForeName>Barbara</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Morel</LastName>
<ForeName>Philippe</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Polonsky</LastName>
<ForeName>Kenneth S</ForeName>
<Initials>KS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Reems</LastName>
<ForeName>Jo-Anna</ForeName>
<Initials>JA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bretzel</LastName>
<ForeName>Reinhard G</ForeName>
<Initials>RG</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bertuzzi</LastName>
<ForeName>Federico</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Froud</LastName>
<ForeName>Tatiana</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kandaswamy</LastName>
<ForeName>Raja</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sutherland</LastName>
<ForeName>David E R</ForeName>
<Initials>DE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Eisenbarth</LastName>
<ForeName>George</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Segal</LastName>
<ForeName>Miriam</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Preiksaitis</LastName>
<ForeName>Jutta</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Korbutt</LastName>
<ForeName>Gregory S</ForeName>
<Initials>GS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Barton</LastName>
<ForeName>Franca B</ForeName>
<Initials>FB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Viviano</LastName>
<ForeName>Lisa</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Seyfert-Margolis</LastName>
<ForeName>Vicki</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bluestone</LastName>
<ForeName>Jeffrey</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lakey</LastName>
<ForeName>Jonathan R T</ForeName>
<Initials>JR</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList>
<AccessionNumber>NCT00014911</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList>
<PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType>
<PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>N Engl J Med</MedlineTA>
<NlmUniqueID>0255562</NlmUniqueID>
<ISSNLinking>0028-4793</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002096">C-Peptide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007518">Isoantibodies</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>N Engl J Med. 2006 Sep 28;355(13):1372-4</RefSource>
<PMID Version="1">17005956</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>N Engl J Med. 2007 Mar 1;356(9):963; author reply 964-5</RefSource>
<PMID Version="1">17329709</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>Curr Diab Rep. 2007 Aug;7(4):301-3</RefSource>
<PMID Version="1">17686407</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>N Engl J Med. 2007 Mar 1;356(9):963-4; author reply 964-5</RefSource>
<PMID Version="1">17338055</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>N Engl J Med. 2007 Mar 1;356(9):964; author reply 964-5</RefSource>
<PMID Version="1">17338054</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>Curr Diab Rep. 2007 Apr;7(2):89; discussion 89-90</RefSource>
<PMID Version="1">17425911</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001786">Blood Glucose</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002096">C-Peptide</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003922">Diabetes Mellitus, Type 1</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005240">Feasibility Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007004">Hypoglycemic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007166">Immunosuppressive Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007262">Infusions, Intravenous</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007328">Insulin</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000078790">Insulin Secretion</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016381">Islets of Langerhans Transplantation</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000592">standards</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007518">Isoantibodies</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009894">Opportunistic Infections</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011169">Portal Vein</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015203">Reproducibility of Results</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019172">Transplantation Conditioning</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000592">standards</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>2006</Year>
<Month>9</Month>
<Day>29</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2006</Year>
<Month>10</Month>
<Day>6</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2006</Year>
<Month>9</Month>
<Day>29</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">17005949</ArticleId>
<ArticleId IdType="pii">355/13/1318</ArticleId>
<ArticleId IdType="doi">10.1056/NEJMoa061267</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>